Resumo

VEGA-DIENSTMAIER, Johann M. Advances in the pharmacological treatment of obsessive-compulsive disorder. Rev Neuropsiquiatr [online]. 2016, vol.79, n.4, pp.239-246. ISSN 0034-8597.  http://dx.doi.org/10.20453/rnp.v79i4.2978.

Serotoninergic antidepressants, the first line of pharmacotherapy for obsessive-compulsive disorder (OCD), induce a favorable clinical response in 40-60% of patients. Drugs that have shown efficacy for OCD treatment, on the basis of different mechanisms of action, are: 1) substance that work on serotonin: serotoninergic antidepressants (selective serotonin reuptake inhibitors and clomipramine), 5-HT3 receptor blockers (ondansetron and granisetron), and 5-HT1A antagonists (pindolol); 2) antipsychotic drugs: aripiprazole, risperidone and haloperidol; 3) anticonvulsant drugs /mood stabilizers: lamotrigine; 4) glutamatergic function-related drugs: memantine, N-acetylcysteine and ketamine; 5) anti-inflammatory drugs: celecoxib; 6) opioid drugs: morphine; 7) drugs that increase cholinergic function; 8) anti-androgen drugs. The repertoire of pharmacological alternatives for the treatment of OCD is expected to grow in the future.

Palavras-chave : Obsessive-compulsive disorder; drug therapy; serotoninergic agents; antipsychotics; glutamatergic function.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )